Answers are grounded in this paper and cite their sources.
Background The objective of the present meta‐analysis was to evaluate the clinicopathological significance and prognosis of micro‐MTC compared to macro‐MTC. Methods Relevant articles were obtained by searching the PubMed and MEDLINE databases. A meta‐analysis was performed using 15 eligible studies. In addition, subgroup analysis based on heredity was performed in patients diagnosed with micro‐MTC. Results The rate of extrathyroidal extension of micro‐MTC [0.118 (95% CI 0.073–0.185)] was significantly lower than that of macro‐MTC [0.303 (95% CI 0.224–0.395)]. Micro‐MTC [0.229 (95% CI 0.161–0.314)] had a significantly lower rate of cervical lymph node (LN) metastasis compared to macro‐MTC [0.595 (95% CI 0.486–0.694)]. The rate of multifocality was not significantly different between micro‐MTC and macro‐MTC [0.394 (95% CI 0.244–0.566) vs. 0.320 (95% CI 0.234–0.421), respectively]. The rate of distant metastasis did not differ significantly between micro‐MTC [0.082 (95% CI 0.017–0.314)] and macro‐MTC [0.068 (95% CI 0.009–0.376)]. Patients with micro‐MTC showed significantly higher disease‐free survival rates [hazard ratio [HR] 0.406 (95% CI 0.288–0.575), I 2 = 40.563%] compared to patients with macro‐MTC. Conclusion Micro‐MTC has aggressive features, such as multifocality and distant metastasis, similar to macro‐MTC and a non‐negligible rate of extrathyroidal extension and cervical LN metastasis. We suggest that treatment of micro‐MTC should be approached with a similar focus as that of macro‐MTC. Considering that less extrathyroidal extension and cervical LN metastasis occur in patients with micro‐MTC compared to macro‐MTC, we propose that treatment of micro‐MTC, which has a relatively low disease burden status, should be viewed as an opportunity for improving prognosis.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: